Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Mallinckrodt
Moodys
Colorcon

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 5,861,502

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 5,861,502
Title: Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
Abstract:The present invention is directed to oligonucleotides that inhibit mutant COL1A1 and/or wild type COL1A1 gene expression. The present invention is further directed to methods of inhibiting mutant and/or wild type collagen gene expression using the disclosed inhibitory oligonucleotides. The oligonucleotides and methods of the present invention are useful for the treatment of mammals having diseases related to inappropriate mutant or wild type COL1A1 gene expression.
Inventor(s): Prockop; Darwin (Philadelphia, PA), Colige; Alain (Sart Tilman Par Liege, BE), Baserga; Renato (Ardmore, PA), Nugent; Paul (Philadelphia, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Application Number:08/432,158
Patent Claims:see list of patent claims

Details for Patent 5,861,502

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Thomas Jefferson University (Philadelphia, PA) 2012-11-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Thomas Jefferson University (Philadelphia, PA) 2012-11-09 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Thomas Jefferson University (Philadelphia, PA) 2012-11-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Dow
Colorcon
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.